Risedronate in the treatment of Murine Chagas' disease

Boumediene Bouzahzah, Linda A. Jelicks, Stephen A. Morris, Louis M. Weiss, Herbert B. Tanowitz

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Risedronate, a bisphosphonate, was used to treat CD-1 mice infected with the Brazil strain of Trypanosoma cruzi. When given by subcutaneous injection 3 times/week, there was a significant reduction in mortality, however, the myocardial pathology and right ventricular dilation was unchanged in these mice compared to control animals. In C57BL/6 mice infected with the Tulahuen strain, there was no change in mortality in response to risedronate treatment. These data suggest that this class of compounds has activity against T. cruzi in vivo and illustrate the utility of imaging and pathologic studies as adjuncts in the evaluation of therapeutic compounds as treatments for experimental Chagas' disease. In addition, it underscores the need to use different strains of T. cruzi.

Original languageEnglish (US)
Pages (from-to)184-187
Number of pages4
JournalParasitology Research
Volume96
Issue number3
DOIs
StatePublished - Jun 1 2005

    Fingerprint

ASJC Scopus subject areas

  • Parasitology
  • veterinary(all)
  • Insect Science
  • Infectious Diseases

Cite this

Bouzahzah, B., Jelicks, L. A., Morris, S. A., Weiss, L. M., & Tanowitz, H. B. (2005). Risedronate in the treatment of Murine Chagas' disease. Parasitology Research, 96(3), 184-187. https://doi.org/10.1007/s00436-005-1331-9